In contrast, IFN-γ plus simvastatin significantly suppressed tumor growth compared with no treatment (p = 0.003), and to a degree highly similar to that seen with DC-based immunotherapy plus simvastatin (Figure 8D). This evidence concerns the gene IFNG and neoplasm.